Clinical Trials Logo

Locoregional Recurrence clinical trials

View clinical trials related to Locoregional Recurrence.

Filter by:
  • None
  • Page 1

NCT ID: NCT06452485 Recruiting - Breast Cancer Clinical Trials

Postoperative Re-irradiaTion With and Without HYPERthermia: Toxicity, Quality of Life and Survival in Patients With Locoregional Recurrent Breast Cancer

RT-HYPE
Start date: January 1, 2024
Phase:
Study type: Observational

In the Netherlands, breast cancer patients with locoregional recurrence (LRR) and high-risk factors are treated with postoperative re-irradiation with or without hyperthermia. Retrospective studies showed that 3-year locoregional control after postoperative re-irradiation with hyperthermia was 68-83%, and severe toxicity in up to 40% of LRR patients. Unfortunately, no prospective (randomized) data are available on clinical outcomes. Consequently, variation exists in hyperthermia-treatment and re-irradiation schedules. Prospective real-world data on oncological outcomes, toxicity and quality of life is highly needed for shared decision-making between patients and professionals. These data will be used in the design of a future randomized trial comparing postoperative re-irradiation and hyperthermia-treatment in high-risk LRR patients.

NCT ID: NCT05988112 Not yet recruiting - Clinical trials for Locoregional Recurrence

Locoregional Recurrence of Breast Cancer

Start date: April 1, 2024
Phase:
Study type: Observational

our study will be retrospective on breast cancer patients to detect relation between the locoregional recurrence of breast cancer after radiotherapy and the molecular subtypes

NCT ID: NCT05467891 Recruiting - Clinical trials for HER2-negative Breast Cancer

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

RaPhLRR
Start date: September 13, 2022
Phase: Phase 2
Study type: Interventional

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.

NCT ID: NCT04550910 Recruiting - Clinical trials for Radiotherapy Side Effect

RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients

Breastcancer
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each week) as adjuvant radiotherapy in female patients with breast cancer after mastectomy.